Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in
vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and
serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum
tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics,
safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies.